News Bristol-Myers Squibb Company BOERSE MUENCHEN

Equities

BRM

US1101221083

Real-time BOERSE MUENCHEN Other stock markets 10:15:07 26/06/2024 BST			5-day change	1st Jan Change
39.54 ^EUR	+0.36%		+3.66%	-15.27%

06-24	Bristol Myers: accelerated approval in colorectal cancer	CF
06-22	Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	06-24	AQ
Bristol Myers: accelerated approval in colorectal cancer	06-24	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	06-22	BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-22	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	06-21	MT
US FDA approves Bristol Myers' colorectal cancer therapy	06-21	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	06-21	MT
Bristol Myers: application validated for subcutaneous Opdivo	06-21	CF
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	06-21	BU
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	06-21	CI
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	06-20	BU
Bristol Myers: ex-CEO of Agilent joins Board of Directors	06-19	CF
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	06-18	BU
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	06-18	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	06-18	MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	06-18	MT
Bristol Myers: Board declares dividend	06-18	CF
Bristol Myers Squibb Announces Dividend	06-18	BU
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	06-18	CI
Bristol Myers: FDA approval for treatment	06-14	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm